Dr. Muller founded TopoGEN, Inc. in 1991. He serves as TopoGEN’s Chairman of the Board of Directors and Scientific Advisory Board. Dr. Muller has been directly responsible for a number of SBIR funding initiatives allowing the growth of the company from 2004- present. He has recently secured joint ventures with other companies to develop novel diagnostics in autoimmune diseases (Multiple Sclerosis, Scleroderma) and bladder cancer. As a result, TopoGEN has been actively expanding its core business. Throughout an almost 30 year career, Dr. Muller has directed successful academic research programs funded by NIH, ACS, NSF and a number of state and local agencies. He has published extensively in peer review journals and has patents on his work. From 1980-2004, Dr. Muller worked at Ohio State University where he participated in the formation of the Department of Molecular Genetics in 1986, one of first academic programs of this nature in the country; he rose to the rank of Full Professor in 1992. In 1991, Dr. Muller did a one year sabbatical with Prof. Michael Smith, a nobel laureate for pioneering work on mutagenesis at the University of British Columbia. In addition, Dr. Muller provided leadership at the OSU Comprehensive Cancer Center in Columbus where he was Co-Director of Experimental Therapeutics Program. With clinical collaborators, he performed bench to bedside experiments and was actively involved in the Phase I and II programs. TopoGEN was initially founded in the OSU Business Incubator (Edison Foundation) and has been awarded a number SBIR grants that have led to spin off companies. In 1997 the company was awarded the Edison Prize as the most innovative start up company in Ohio. In 2004, Dr. Muller was recruited to join the University of Central Florida where he participated in the formation of a new Medical School and he joined the College of Medicine in 2007 where he is also Professor of Molecular Biology and Microbiology. Dr. Muller sits a several Company Advisory Boards (besides TopoGEN) and has founded other biotechnology startups including Visual Genomics, Methylation Ltd., DNA Protein, Ltd. and CareCyte Biologicals. He has multiple international collaborations with colleagues in South Africa, Italy, Japan, Korea and the UK and is currently the Director of the Cancer Research Consortium of Central Florida. Dr. Muller is active on editorial boards and acts as an outside reviewer for several different journals, including PNAS, EMBO Journal, Cancer Research, PLoS Biology and Genetics.
Mr. Brandkamp has been with the company since its founding and was instrumental in bringing it to profitability. He has worked extensively with small are large companies around the country with emphasis on Ohio and Florida. Mr. Brandkamp brings over 20 years of business and accounting experience to the company. He is also President of Thomas W. Brandkamp and Company, a successful accounting firm located in Columbus, Ohio.
Mr. Bevil has over 30 years of commercial lending experience. He has served on a number of boards in the banking industry and was President of Texas State Bank in the Dallas market. He also worked for many years with the Compass Bank in Dallas managing their commercial banking division. Mr. Bevil has held other management positions with Compass Bank, mostly in Commercial Lending and Commercial Deposit generation. His primary focus has been on owner managed businesses. Additional experience is in the sale of Treasury Management products and servicing title company businesses. Mr. Bevil left Compass to be the Dallas Market President for Texas State Bank. Mr. Bevil is a graduate of the University of Texas (Austin) and a 1983 Graduate of The Southwestern Graduate School of Banking at SMU. He also did study work for the New York Institute of Finance in preparation of obtaining a Series 7 Securities license.